

Mohammad A Rafi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2382989/publications.pdf>

Version: 2024-02-01

41
papers

1,992
citations

257101

24
h-index

288905

40
g-index

41
all docs

41
docs citations

41
times ranked

1771
citing authors

#	ARTICLE	IF	CITATIONS
1	Krabbe disease: A personal perspective and hypothesis.. BiolImpacts, 2022, 12, 3-7.	0.7	1
2	Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?. BiolImpacts, 2021, 11, 135-146.	0.7	10
3	Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses. Expert Opinion on Biological Therapy, 2021, 21, 1181-1197.	1.4	3
4	Advances in the Diagnosis and Treatment of Krabbe Disease. International Journal of Neonatal Screening, 2021, 7, 57.	1.2	9
5	Mathematical Models to Shed Light on Amyloid-Beta and Tau Protein Dependent Pathologies in Alzheimer's Disease. Neuroscience, 2020, 424, 45-57.	1.1	10
6	Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours. Journal of Drug Targeting, 2020, 28, 700-713.	2.1	24
7	Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discovery Today, 2020, 25, 1034-1042.	3.2	120
8	Conditions for combining gene therapy with bone marrow transplantation in murine Krabbe disease. BiolImpacts, 2020, 10, 105-115.	0.7	18
9	BiolImpacts: An emerging global journal. BiolImpacts, 2020, 10, 207-208.	0.7	1
10	Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery, 2019, 16, 583-605.	2.4	45
11	Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis. Cellular and Molecular Life Sciences, 2019, 76, 3363-3381.	2.4	16
12	Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. Journal of Drug Targeting, 2018, 26, 95-109.	2.1	35
13	Spectrophotometric analysis of thrombolytic activity: SATA assay. BiolImpacts, 2018, 8, 31-38.	0.7	8
14	Enzyme replacement therapies: what is the best option?. BiolImpacts, 2018, 8, 153-157.	0.7	41
15	Debate on human aging and lifespan. BiolImpacts, 2017, 7, 135-137.	0.7	12
16	Blood-brain barrier transport machineries and targeted therapy of brain diseases. BiolImpacts, 2016, 6, 225-248.	0.7	174
17	Krabbe disease: One Hundred years from the bedside to the bench to the bedside. Journal of Neuroscience Research, 2016, 94, 982-989.	1.3	31
18	Gene therapy for CNS diseases – Krabbe disease. BiolImpacts, 2016, 6, 69-70.	0.7	4

#	ARTICLE	IF	CITATIONS
19	To impact or not to impact, this is not a question for BiolImpacts!. BiolImpacts, 2015, 5, 1-2.	0.7	13
20	Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features. Molecular Genetics and Metabolism, 2015, 114, 459-466.	0.5	43
21	Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice. Molecular Therapy, 2015, 23, 1681-1690.	3.7	52
22	A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination. BiolImpacts, 2015, 5, 117-122.	0.7	16
23	Krabbe disease: Are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations?. Molecular Genetics and Metabolism, 2014, 111, 307-308.	0.5	34
24	Lysosomal storage diseases: heterogeneous group of disorders. BiolImpacts, 2013, 3, 145-7.	0.7	9
25	Extended Normal Life After AAVrh10-mediated Gene Therapy in the Mouse Model of Krabbe Disease. Molecular Therapy, 2012, 20, 2031-2042.	3.7	93
26	Gene and stem cell therapy: alone or in combination?. BiolImpacts, 2011, 1, 213-8.	0.7	16
27	Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Research, 2009, 1300, 146-158.	1.1	64
28	Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Molecular Genetics and Metabolism, 2009, 97, 27-34.	0.5	40
29	AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Molecular Therapy, 2005, 12, 422-430.	3.7	89
30	AAV-Mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Molecular Therapy, 2005, 11, 734-744.	3.7	95
31	Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation. Molecular Genetics and Metabolism, 2005, 86, 150-159.	0.5	29
32	Disease-causing mutations in cis with the common arylsulfatase A pseudodeficiency allele compound the difficulties in accurately identifying patients and carriers of metachromatic leukodystrophy. Molecular Genetics and Metabolism, 2003, 79, 83-90.	0.5	40
33	Transduction of cultured oligodendrocytes from normal and twitcher mice by a retroviral vector containing human galactocerebrosidase (GALC) cDNA. Neurochemical Research, 1999, 24, 287-293.	1.6	24
34	Molecular genetics of Krabbe disease (globoid cell leukodystrophy): Diagnostic and clinical implications. , 1997, 10, 268-279.		197
35	Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel. Human Genetics, 1996, 97, 304-308.	1.8	64
36	Retroviral Vector-Mediated Transfer of the Galactocerebrosidase (GALC) cDNA Leads to Overexpression and Transfer of GALC Activity to Neighboring Cells. Biochemical and Molecular Medicine, 1996, 58, 142-150.	1.5	40

#	ARTICLE	IF	CITATIONS
37	Multiple mutations in the GALC gene in a patient with adult-onset krabbe disease. <i>Annals of Neurology</i> , 1996, 40, 116-119.	2.8	58
38	A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. <i>Human Molecular Genetics</i> , 1995, 4, 1285-1289.	1.4	108
39	Structure and organization of the human galactocerebrosidase (GALC) gene. <i>Genomics</i> , 1995, 26, 407-409.	1.3	86
40	Characterization of the large deletion in the GALC gene found in patients with Krabbe disease. <i>Human Molecular Genetics</i> , 1995, 4, 2335-2338.	1.4	75
41	Cloning and expression cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. <i>Human Molecular Genetics</i> , 1993, 2, 1841-1846.	1.4	145